Section Arrow
Quote
ALGS.NASDAQ
- Aligos Therapeutics Inc
Quotes are at least 15-min delayed:2025/11/16 10:58 EST
Regular Hours
Last
 6.66
+0.59 (+9.72%)
Day High 
6.73 
Prev. Close
6.07 
1-M High
11.22 
Volume 
72.03K 
Bid
6.3
Ask
6.78
Day Low
5.81 
Open
5.88 
1-M Low
5.93 
Market Cap 
37.35M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 7.06 
20-SMA 8.32 
50-SMA 9.37 
52-W High 46.8 
52-W Low 3.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.27/-8.81
Enterprise Value
42.27M
Balance Sheet
Book Value Per Share
11.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.95M
Operating Revenue Per Share
2.66
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 10:58 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.